Enrollment on upfront high-risk neuroblastoma trials by race, ethnicity, and poverty status: A report from the Children's Oncology Group

Puja J. Umaretiya; Arlene Naranjo; Fan F. Zhang; Meredith S. Irwin; Steven G. DuBois; Rochelle Bagatell; Kira Bona

doi:10.1002/pbc.31051

Enrollment on upfront high-risk neuroblastoma trials by race, ethnicity, and poverty status: A report from the Children's Oncology Group

Puja J. Umaretiya, Arlene Naranjo, Fan F. Zhang, Meredith S. Irwin, Steven G. DuBois, Rochelle Bagatell, Kira Bona

Research output: Contribution to journal › Article › peer-review

Abstract

It is not clear whether trial access disparities exist in the Children's Oncology Group (COG). Here, we leverage a cohort of children with high-risk neuroblastoma (HR-NBL) enrolled on the COG ANBL00B1 neuroblastoma biology study to examine subsequent enrollment to upfront COG therapeutic trials by race, ethnicity, and proxied poverty status. Among 1917 children with HR-NBL enrolled on ANBL00B1, 696 (36.3%) subsequently enrolled on an upfront therapeutic trial with no difference by race, ethnicity, or proxied poverty status. In neuroblastoma, trial access disparities are not comparable to adult oncology, and efforts to advance equity should prioritize other mechanisms of survival disparities.

Original language	English
Article number	e31051
Journal	Pediatric Blood and Cancer
Volume	71
Issue number	7
DOIs	https://doi.org/10.1002/pbc.31051
State	Published - Jul 2024
Externally published	Yes

Keywords

disparities
ethnicity
neuroblastoma
poverty
race

Access to Document

10.1002/pbc.31051

Cite this

@article{4ac49dc526d745dc98e81420a5d852e3,

title = "Enrollment on upfront high-risk neuroblastoma trials by race, ethnicity, and poverty status: A report from the Children's Oncology Group",

abstract = "It is not clear whether trial access disparities exist in the Children's Oncology Group (COG). Here, we leverage a cohort of children with high-risk neuroblastoma (HR-NBL) enrolled on the COG ANBL00B1 neuroblastoma biology study to examine subsequent enrollment to upfront COG therapeutic trials by race, ethnicity, and proxied poverty status. Among 1917 children with HR-NBL enrolled on ANBL00B1, 696 (36.3%) subsequently enrolled on an upfront therapeutic trial with no difference by race, ethnicity, or proxied poverty status. In neuroblastoma, trial access disparities are not comparable to adult oncology, and efforts to advance equity should prioritize other mechanisms of survival disparities.",

keywords = "disparities, ethnicity, neuroblastoma, poverty, race",

author = "Umaretiya, {Puja J.} and Arlene Naranjo and Zhang, {Fan F.} and Irwin, {Meredith S.} and DuBois, {Steven G.} and Rochelle Bagatell and Kira Bona",

note = "Publisher Copyright: {\textcopyright} 2024 Wiley Periodicals LLC.",

year = "2024",

month = jul,

doi = "10.1002/pbc.31051",

language = "English",

volume = "71",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

number = "7",

}

TY - JOUR

T1 - Enrollment on upfront high-risk neuroblastoma trials by race, ethnicity, and poverty status

T2 - A report from the Children's Oncology Group

AU - Umaretiya, Puja J.

AU - Naranjo, Arlene

AU - Zhang, Fan F.

AU - Irwin, Meredith S.

AU - DuBois, Steven G.

AU - Bagatell, Rochelle

AU - Bona, Kira

PY - 2024/7

Y1 - 2024/7

N2 - It is not clear whether trial access disparities exist in the Children's Oncology Group (COG). Here, we leverage a cohort of children with high-risk neuroblastoma (HR-NBL) enrolled on the COG ANBL00B1 neuroblastoma biology study to examine subsequent enrollment to upfront COG therapeutic trials by race, ethnicity, and proxied poverty status. Among 1917 children with HR-NBL enrolled on ANBL00B1, 696 (36.3%) subsequently enrolled on an upfront therapeutic trial with no difference by race, ethnicity, or proxied poverty status. In neuroblastoma, trial access disparities are not comparable to adult oncology, and efforts to advance equity should prioritize other mechanisms of survival disparities.

AB - It is not clear whether trial access disparities exist in the Children's Oncology Group (COG). Here, we leverage a cohort of children with high-risk neuroblastoma (HR-NBL) enrolled on the COG ANBL00B1 neuroblastoma biology study to examine subsequent enrollment to upfront COG therapeutic trials by race, ethnicity, and proxied poverty status. Among 1917 children with HR-NBL enrolled on ANBL00B1, 696 (36.3%) subsequently enrolled on an upfront therapeutic trial with no difference by race, ethnicity, or proxied poverty status. In neuroblastoma, trial access disparities are not comparable to adult oncology, and efforts to advance equity should prioritize other mechanisms of survival disparities.

KW - disparities

KW - ethnicity

KW - neuroblastoma

KW - poverty

KW - race

UR - http://www.scopus.com/inward/record.url?scp=85192182607&partnerID=8YFLogxK

U2 - 10.1002/pbc.31051

DO - 10.1002/pbc.31051

M3 - Article

AN - SCOPUS:85192182607

SN - 1545-5009

VL - 71

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

IS - 7

M1 - e31051

ER -

Enrollment on upfront high-risk neuroblastoma trials by race, ethnicity, and poverty status: A report from the Children's Oncology Group

Abstract

Keywords

Access to Document

Fingerprint

Cite this